Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT04796012
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT04790448
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Azienda Unità Sanitaria Locale Reggio Emilia
- Target Recruit Count
- 280
- Registration Number
- NCT04776655
- Locations
- 🇮🇹
Azienda ULSS 3 Serenissima, Mirano, VE, Italy
🇮🇹Ospedale Civile di Guastalla, Guastalla, Reggio Emilia, Italy
🇮🇹Ospedale San Salvatore, Coppito, L'Aquila, Italy
Docetaxel and Irinotecan in Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Menoufia University
- Target Recruit Count
- 32
- Registration Number
- NCT04770623
- Locations
- 🇪🇬
Menoufia University, Faculty of medicine, Shibīn Al Kawm, Menoufia, Egypt
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-08-23
- Target Recruit Count
- 38
- Registration Number
- NCT04753879
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 62
- Registration Number
- NCT04743661
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 119
- Registration Number
- NCT04728035
- Locations
- 🇨🇳
Cancer Hosptial of CAMS, Beijing, Beijing, China
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04727853
- Locations
- 🇨🇳
Jilin Cancer Hospital, Chang Chun, Jilin, China
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇮🇹Fondazione Policlinico Universitario Agostino, Roma, Other, Italy
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-04-04
- Target Recruit Count
- 18
- Registration Number
- NCT04689347
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.